Spark Therapeutics (ONCE) Shares Down 0%

Spark Therapeutics Inc (NASDAQ:ONCE)’s share price dropped 0% during trading on Tuesday . The stock traded as low as $50.06 and last traded at $50.23. Approximately 1,442,221 shares traded hands during trading, an increase of 87% from the average daily volume of 772,221 shares. The stock had previously closed at $50.23.

ONCE has been the subject of several research analyst reports. SunTrust Banks upped their target price on shares of Spark Therapeutics to $113.00 and gave the company a “buy” rating in a research note on Thursday, January 4th. Credit Suisse Group initiated coverage on shares of Spark Therapeutics in a research note on Wednesday, January 17th. They set an “outperform” rating and a $61.00 target price for the company. Cantor Fitzgerald set a $105.00 target price on shares of Spark Therapeutics and gave the company a “buy” rating in a research note on Tuesday, December 19th. Raymond James Financial reiterated a “buy” rating and set a $75.00 target price on shares of Spark Therapeutics in a research note on Thursday, December 7th. Finally, Goldman Sachs Group cut shares of Spark Therapeutics from a “buy” rating to a “neutral” rating and cut their target price for the company from $106.00 to $58.00 in a research note on Thursday, December 14th. They noted that the move was a valuation call. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and seventeen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $72.63.

The firm has a market capitalization of $1,860.00, a P/E ratio of -6.98 and a beta of 3.02.

In other news, insider Katherine A. High sold 5,000 shares of the stock in a transaction on Tuesday, November 28th. The shares were sold at an average price of $71.32, for a total value of $356,600.00. Following the completion of the transaction, the insider now owns 215,000 shares in the company, valued at approximately $15,333,800. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 7.30% of the company’s stock.

Several hedge funds have recently made changes to their positions in ONCE. Cornerstone Capital Management Holdings LLC. grew its holdings in shares of Spark Therapeutics by 3.2% in the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 11,089 shares of the biotechnology company’s stock worth $662,000 after purchasing an additional 342 shares during the last quarter. Ameritas Investment Partners Inc. grew its holdings in shares of Spark Therapeutics by 23.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock worth $122,000 after purchasing an additional 389 shares during the last quarter. California Public Employees Retirement System grew its holdings in shares of Spark Therapeutics by 2.1% in the 2nd quarter. California Public Employees Retirement System now owns 39,100 shares of the biotechnology company’s stock worth $2,336,000 after purchasing an additional 800 shares during the last quarter. Aperio Group LLC grew its holdings in shares of Spark Therapeutics by 29.2% in the 4th quarter. Aperio Group LLC now owns 3,972 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 898 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Spark Therapeutics by 5.0% in the 4th quarter. The Manufacturers Life Insurance Company now owns 21,428 shares of the biotechnology company’s stock worth $1,102,000 after purchasing an additional 1,013 shares during the last quarter.

TRADEMARK VIOLATION WARNING: “Spark Therapeutics (ONCE) Shares Down 0%” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/20/spark-therapeutics-once-shares-down-0.html.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply